Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
July 26, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a...
Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings
July 07, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Multiple Podium and Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - ALPHARETTA, Ga., July 07, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:...
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
June 14, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference
June 08, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 16:05 ET
|
Clearside Biomedical, Inc.
- First Approved Suprachoroidal Product, XIPERE®, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase 1/2a Trial - - Management to Host Webcast...
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
May 05, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - - Dr. Thomas Ciulla to Participate in a Panel Discussion at Retina World Congress 2022 on May 12,...
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
April 29, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
April 06, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 10, 2022 16:05 ET
|
Clearside Biomedical, Inc.
- XIPERE® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 - - Continued Progress in CLS-AX OASIS Wet AMD Phase 1/2a Trial with Cohort 3 Results Expected Mid-2022 - -...
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
March 03, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...